JP2013517461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517461A5 JP2013517461A5 JP2012548241A JP2012548241A JP2013517461A5 JP 2013517461 A5 JP2013517461 A5 JP 2013517461A5 JP 2012548241 A JP2012548241 A JP 2012548241A JP 2012548241 A JP2012548241 A JP 2012548241A JP 2013517461 A5 JP2013517461 A5 JP 2013517461A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- her1
- kit
- level
- vegfr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 13
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 10
- 102000001301 EGF receptor Human genes 0.000 claims 10
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 10
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 10
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 9
- 239000000284 extract Substances 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- -1 c-KIT Proteins 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000011088 calibration curve Methods 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 claims 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 claims 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29443310P | 2010-01-12 | 2010-01-12 | |
| US61/294,433 | 2010-01-12 | ||
| US32562410P | 2010-04-19 | 2010-04-19 | |
| US61/325,624 | 2010-04-19 | ||
| US32860210P | 2010-04-27 | 2010-04-27 | |
| US61/328,602 | 2010-04-27 | ||
| US35183810P | 2010-06-04 | 2010-06-04 | |
| US61/351,838 | 2010-06-04 | ||
| PCT/US2011/021026 WO2011088149A2 (en) | 2010-01-12 | 2011-01-12 | Methods for predicting response of triple-negative breast cancer to therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517461A JP2013517461A (ja) | 2013-05-16 |
| JP2013517461A5 true JP2013517461A5 (enExample) | 2014-02-27 |
| JP5764144B2 JP5764144B2 (ja) | 2015-08-12 |
Family
ID=44304951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548241A Expired - Fee Related JP5764144B2 (ja) | 2010-01-12 | 2011-01-12 | 治療法に対するトリプルネガティブ乳癌の反応を予測するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9488654B2 (enExample) |
| EP (1) | EP2524232B1 (enExample) |
| JP (1) | JP5764144B2 (enExample) |
| KR (1) | KR20120115390A (enExample) |
| CN (1) | CN102822676B (enExample) |
| AU (1) | AU2011205343B2 (enExample) |
| BR (1) | BR112012017084A2 (enExample) |
| CA (1) | CA2787225A1 (enExample) |
| ES (1) | ES2505466T3 (enExample) |
| IL (1) | IL220833A0 (enExample) |
| MX (1) | MX2012008153A (enExample) |
| NZ (1) | NZ601348A (enExample) |
| RU (1) | RU2558931C2 (enExample) |
| WO (1) | WO2011088149A2 (enExample) |
| ZA (1) | ZA201206019B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| EP2788752B1 (en) * | 2011-12-05 | 2018-10-03 | Pierian Holdings, Inc. | Method of therapy selection for patients with lung cancer |
| CA2862835A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| WO2014001232A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| US9422602B2 (en) | 2012-08-15 | 2016-08-23 | Bio-Rad Laboratories, Inc. | Methods and compositions for determining nucleic acid degradation |
| WO2014071218A2 (en) * | 2012-11-02 | 2014-05-08 | University Of Utah Research Foundation | Biomarkers for breast cancer and methods of using same |
| KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| WO2015028974A2 (en) * | 2013-08-30 | 2015-03-05 | Nestec S.A. | Polyp recurrence |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| EP3006940A1 (en) * | 2014-10-10 | 2016-04-13 | Ruprecht-Karls-Universität Heidelberg | Biomarkers for predicting the response to anti-angiogenic cancer therapy |
| CN105891496A (zh) * | 2014-12-09 | 2016-08-24 | 上海华盈生物医药科技有限公司 | 酪氨酸激酶抑制剂类靶向用药指导抗体芯片和检测方法 |
| CN104830775B (zh) * | 2015-04-14 | 2019-06-21 | 上海中医药大学附属龙华医院 | 一种三阴性乳腺癌顺铂耐药细胞株及其制备方法和用途 |
| HRP20260689T1 (hr) | 2015-06-17 | 2026-07-17 | F. Hoffmann-La Roche Ag | Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana |
| US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
| EP3363911B1 (en) * | 2015-10-14 | 2024-09-25 | Nitto Boseki Co., Ltd. | Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used |
| RU2616533C1 (ru) * | 2016-03-15 | 2017-04-17 | Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) | Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| CN109789204A (zh) * | 2016-05-31 | 2019-05-21 | 雀巢产品技术援助有限公司 | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 |
| CN106645728A (zh) * | 2016-11-09 | 2017-05-10 | 百奥森（江苏）食品安全科技有限公司 | 一种食品中氟喹诺酮类药物的检测试剂盒 |
| RU2648523C1 (ru) * | 2017-05-22 | 2018-03-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию |
| CN109470854B (zh) * | 2017-09-08 | 2022-02-11 | 广州市丹蓝生物科技有限公司 | 肺癌诊断用蛋白芯片及试剂盒 |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20210088523A1 (en) * | 2019-09-23 | 2021-03-25 | Sri International | Methods for detecting circulating tumor cells in non-small cell lung cancer |
| US11366101B1 (en) | 2020-12-31 | 2022-06-21 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
| CN120731084A (zh) * | 2023-03-15 | 2025-09-30 | 侯明宏 | 用于治疗三阴性乳癌的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| WO1995006877A1 (en) | 1993-09-03 | 1995-03-09 | Behringwerke Ag | Fluorescent oxygen channeling immunoassays |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
| US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
| CA2418105A1 (en) | 2000-08-03 | 2002-02-14 | Massachusetts Institute Of Technology | Microarrays of functional biomolecules, and uses therefor |
| AU2002303384A1 (en) | 2001-04-17 | 2002-10-28 | William J. Dower | Epitope-captured antibody display |
| US20030153013A1 (en) | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
| US20060263837A1 (en) | 2004-06-17 | 2006-11-23 | Liu George D | Immunoassay system and method for detection of antigens |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US7771955B2 (en) | 2005-06-09 | 2010-08-10 | University Of Maryland | Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule |
| CN104198705B (zh) * | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
| RU2341198C2 (ru) * | 2006-11-27 | 2008-12-20 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ оценки ангиогенных факторов при химиотерапии рака молочной железы |
| EP2109686A2 (en) * | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| JP2010540459A (ja) * | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法 |
| ES2553390T3 (es) * | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
| NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| CA2804350A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
-
2011
- 2011-01-12 RU RU2012134390/15A patent/RU2558931C2/ru not_active IP Right Cessation
- 2011-01-12 KR KR1020127021091A patent/KR20120115390A/ko not_active Ceased
- 2011-01-12 CA CA2787225A patent/CA2787225A1/en not_active Abandoned
- 2011-01-12 CN CN201180013380.7A patent/CN102822676B/zh not_active Expired - Fee Related
- 2011-01-12 BR BR112012017084A patent/BR112012017084A2/pt not_active IP Right Cessation
- 2011-01-12 JP JP2012548241A patent/JP5764144B2/ja not_active Expired - Fee Related
- 2011-01-12 AU AU2011205343A patent/AU2011205343B2/en not_active Ceased
- 2011-01-12 MX MX2012008153A patent/MX2012008153A/es active IP Right Grant
- 2011-01-12 EP EP11733335.1A patent/EP2524232B1/en active Active
- 2011-01-12 NZ NZ601348A patent/NZ601348A/en not_active IP Right Cessation
- 2011-01-12 ES ES11733335.1T patent/ES2505466T3/es active Active
- 2011-01-12 WO PCT/US2011/021026 patent/WO2011088149A2/en not_active Ceased
-
2012
- 2012-07-09 IL IL220833A patent/IL220833A0/en unknown
- 2012-07-10 US US13/545,947 patent/US9488654B2/en not_active Expired - Fee Related
- 2012-08-10 ZA ZA2012/06019A patent/ZA201206019B/en unknown
-
2016
- 2016-09-20 US US15/270,998 patent/US10697967B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134390A (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
| Hegde et al. | Top 10 challenges in cancer immunotherapy | |
| JP2011514522A5 (enExample) | ||
| Metropulos et al. | The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial | |
| Damia et al. | Platinum resistance in ovarian cancer: role of DNA repair | |
| JP2012533738A5 (enExample) | ||
| JP2012526992A5 (enExample) | ||
| Jhaveri et al. | HSP90 inhibitors for cancer therapy and overcoming drug resistance | |
| Gonzalez de Castro et al. | Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance | |
| Manzoni et al. | Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer | |
| JOP20140128B1 (ar) | تركيبة علاجية تشتمل على مثبط b_raf ومثبط ثان | |
| JP2015505959A5 (enExample) | ||
| JP2017524002A5 (enExample) | ||
| JP2011506917A5 (enExample) | ||
| ATE510929T1 (de) | Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozyten | |
| Blauwhoff-Buskermolen et al. | ‘Pre-cachexia’: a non-existing phenomenon in cancer? | |
| JP2015529199A5 (enExample) | ||
| Li et al. | The use of prognostic factors in metastatic renal cell carcinoma | |
| JP2016517960A (ja) | Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法 | |
| WO2011093675A3 (ko) | 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커 | |
| WO2010150254A3 (en) | A method and system for the detection of cancer | |
| Li et al. | Multifunctional gold nanoparticle based selective detection of esophageal squamous cell carcinoma cells using resonance Rayleigh scattering assay | |
| WO2010096734A3 (en) | B7-h3 antibody coupled bead assay for detection of circulating tumor cells | |
| Muhetarijiang et al. | A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis | |
| Li et al. | Cancer stem cell biomarkers in the nervous system |